

■ **Novavax, Inc. has announced the receipt of funding from the US National Institutes of Health (NIH) to develop a SARS* vaccine** using its proprietary virus-like particle (VLP) technology. The grant of just over \$US1 million over 3 years will assist Novavax in its development of a VLP vaccine for proof of concept studies in preparation for human trials. President of Novavax Inc. Nelson M Sims notes that *"our proprietary VLP technology, and its clinical advantages, are gaining acceptance among vaccine experts as an alternative to traditional vaccine technology"*.

* severe acute respiratory syndrome

Novavax Inc. Novavax Receives SARS Vaccine Funding From NIH. Media Release : 4 Feb 2005. Available from: URL: <http://www.novavax.com>

809044872